Ask AI
Optimizing Oral Targeted Therapies in HRpos HER2neg Breast Cancer

CE

Optimizing the Use of Targeted Therapies in Breast Cancer: Dosing, Toxicity Management, and Adherence

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: July 28, 2026

Expiration: January 27, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. Abemaciclib [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2025.
  2. Palbociclib [prescribing information]. New York, NY: Pfizer Labs; 2026.
  3. Ribociclib [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2026.
  4. Spring LM, Zangardi ML, Moy B, et al. Clinical management of potential toxicities and drug interactions
  5. related to cyclin‐dependent kinase 4/6 inhibitors in breast cancer: practical considerations and
  6. recommendations. Oncologist. 2017;22:1039-1048.
  7. Hamilton E, Decker T, Rugo HS, et al. Impact of ribociclib dose reduction on efficacy in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) early breast cancer (EBC) in NATALEE. Presented at: 2024 San Antonio Breast Cancer Symposium. December 10-13, 2024. Abstract P1-11-16.
  8. Mayer EL, Trapani D, Kim SE, et al. The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer. Presented at: 2025 American Society of Clinical Oncology Annual Conference. May 30-June 3, 2025. Abstract 517.
  9. Mayer EL, Trapani D, Kim SE, et al. TRADE: A phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer. Ann Oncol. 2026;37:117-124.
  10. Alpelisib [prescribing information]. East Hanover, NJ: Novartis; 2025.
  11. Capivasertib [prescribing information]. Wilmington, DE: AstraZeneca; 2026.
  12. 10. Inavolisib [prescribing information]. South San Francisco, CA: Genentech; 2026.
  13. Llombart-Cussac A, Pérez-Garcia JM, Borrego MR, et al. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial. eClinicalMedicine. 2024;71:102520.
  14. Olaparib [prescribing information]. Wilmington, DE: AstraZeneca; 2025.
  15. Talazoparib [prescribing information]. New York, NY: Pfizer; 2025.
  16. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523-533.
  17. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA Mutation. N Engl J Med. 2018;379:753-763.
  18. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: antiemesis. v.1.2026. nccn.org. Accessed July 23, 2026.
  19. Elacestrant [prescribing information]. New York, NY: Stemline Therapeutics, Inc; 2023.
  20. Imlunestrant [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2025.
  21. Vepdegestrant [prescribing information]. New Haven, CT: Arvinas Operations, Inc.; 2026.